Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin versus placebo for prevention of postherpetic neuralgia
ISRCTN79871784Phase 3Completed
- Sponsor
- Gerencia de Atención Primaria de Mallorca
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing Gabapentin + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: Prevalence of postherpetic neuralgia at 12 weeks. Started May 2013; status: completed.
02
Drugs
gabapentin
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ISRCTN79871784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79871784.